TCBP vs. ACORQ, SCNI, ACOR, SQZ, GMDAQ, GMDA, WINT, ELOX, ALBT, and KRBP
Should you be buying TC Biopharm stock or one of its competitors? The main competitors of TC Biopharm include Acorda Therapeutics (ACORQ), Scinai Immunotherapeutics (SCNI), Acorda Therapeutics (ACOR), SQZ Biotechnologies (SQZ), Gamida Cell (GMDAQ), Gamida Cell (GMDA), Windtree Therapeutics (WINT), Eloxx Pharmaceuticals (ELOX), Avalon GloboCare (ALBT), and Kiromic BioPharma (KRBP). These companies are all part of the "biological products, except diagnostic" industry.
TC Biopharm (NASDAQ:TCBP) and Acorda Therapeutics (NASDAQ:ACORQ) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.
TC Biopharm has a net margin of 0.00% compared to Acorda Therapeutics' net margin of -214.95%. TC Biopharm's return on equity of 0.00% beat Acorda Therapeutics' return on equity.
TC Biopharm received 1 more outperform votes than Acorda Therapeutics when rated by MarketBeat users.
TC Biopharm has higher earnings, but lower revenue than Acorda Therapeutics.
In the previous week, TC Biopharm had 6 more articles in the media than Acorda Therapeutics. MarketBeat recorded 6 mentions for TC Biopharm and 0 mentions for Acorda Therapeutics. TC Biopharm's average media sentiment score of 0.28 beat Acorda Therapeutics' score of 0.00 indicating that TC Biopharm is being referred to more favorably in the media.
16.3% of TC Biopharm shares are held by institutional investors. Comparatively, 12.7% of Acorda Therapeutics shares are held by institutional investors. 0.1% of TC Biopharm shares are held by insiders. Comparatively, 2.6% of Acorda Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
TC Biopharm has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500.
Summary
TC Biopharm beats Acorda Therapeutics on 9 of the 12 factors compared between the two stocks.
Get TC Biopharm News Delivered to You Automatically
Sign up to receive the latest news and ratings for TCBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TCBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TC Biopharm Competitors List
Related Companies and Tools
